A pen injection device for self-administration of recombinant follicle-stimulating hormone for fertility treatments

Expert Review of Medical Devices

Volumn 2, Issue 1, 2005, Pages 27-32

  Pang, Samuel C ^a  

^a Reproductive Science Center   (United States)

Author keywords

Assisted reproductive technology; Follistim; Follitropin ; Puregon; Recombinant follicle stimulating hormone

Indexed keywords

RECOMBINANT FOLLITROPIN;

ACCURACY; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; INJECTION PAIN; META ANALYSIS; NEEDLE; OVULATION INDUCTION; PRESCRIPTION; REVIEW; SAFETY; SELF INJECTION; SYSTEMATIC REVIEW;

EID: 12344274435     PISSN: 17434440     EISSN: None     Source Type: Journal    
DOI: 10.1586/17434440.2.1.27     Document Type: Review

References (21)

1. Stephen EH, Chandra A. Updated projections of infertility in the United States: 1995-2025. Fertil. Steril. 70(1), 30-34 (1998).
2. American Society for Reproductive Medicine. Assisted reproductive technology in the United States: 2000 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil. Steril. 81(5), 1207-1220 (2004).
3. National Collaborating Centre for Women's and Children's Health. Fertility: Assessment and Treatment for People with Fertility Problems. RCOG Press, London, UK (2004).
4. Loumaye E. Martineau I, Piazzi A et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Hum. Reprod. 11 (Suppl.), 195-107 (1996).
5. Coelingh Bennink HJ, Fauser BC, Out HJ. Recombinant follicle-stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: a prospective, multicenter, assessor-blind, randomized, clinical trial. European Puregon Collaborative Anovulation Study Group. Fertil Steril. 69(1), 19-25 (1998).
6. Lambert A, Rodgers M, Mitchell R et al. In vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP. Hum. Reprod. 10(7), 1928-1935 (1995).
7. Steelman SL, Pohley FM. Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin. Endocrinology 53(6), 604-616(1953).
8. Olijve W. Molecular cloning, production, and properties of recombinant FSH (Puregon®.) Gekkan Soshiki Baiyo Kogaku 25, 28-33 (1999).
9. Horsman G, Talbot JA, McLoughlin JD, Lambert A, Robertson WR. A biological, immunological and physicochemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon. Hum. Reprod. 15(9), 1898-1902 (2000).
10. Mannaerts BM, Rombout F, Out HJ, Coelingh BH. Clinical profiling of recombinant follicle-stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Hum. Reprod. Update. 2(2), 153-161 (1996).
11. Shoham Z, Insler V. Recombinant technique and gonadotropins production: new era in reproductive medicine. Fertil. Steril. 66(2), 187-201 (1996).
12. Recombinant Human FSH Product Development Group. Recombinant follicle stimulating hormone- development of the first biotechnology product for the treatment of infertility. Recombinant Human FSH Product Development Group. Hum. Reprod. Update 4(6), 862-881 (1998).
13. Out HJ, Lindenberg S, Mikkelsen AL et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle-stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum. Reprod. 14(3), 622-627 (1999).
14. Kadiri A, Chraibi A, Marouan F et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res. Clin. Pract. 41 (1), 15-23 (1998).
15. Bohannon NJ. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad Med. 106(5), 57-54 (1999).
16. Kettel LM, Scholl G, Bonaventura L et al. Evaluation of a pen device for self-administration of recombinant human follicle-stimulating hormone in clomiphene citrate-resistant anovulatory women undergoing ovulation induction. Reprod. Biomed. Online 9(4), 373-380 (2004).
17. Pang SC, Kaplan B, Karande V et al. Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation. Reprod. Biomed. Online 7(3), 319-326 (2003).
18. Voortman G, van de Post J, Schoemaker RC, van Gerven JM. Bioequivalence of subcutaneous injections of recombinant human follicle-stimulating hormone (Puregon®) by Pen injector and syringe. Hum. Reprod. 14(7), 1698-1702 (1999).
19. Craenmehr E, Bontje PM, Hoomans E, Voortman G, Mannaerts BM. Follitropin-β administered by pen device has superior local tolerance compared with follitropin-α administered by conventional syringe. Reprod. Biomed. Online 3(3), 185-189 (2001).
20. Platteau P, Laurent E, Albano C et al. An open, randomized single-centre study to compare the efficacy and convenience of follitropin-α administered by a pen device with follitropin-α administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI. Hum. Reprod. 18(6), 1200-1204 (2003).
21. Lavery SA, Paul E, Turner C, Margara R, Trew G. Evaluation of a needle-free vehicle for administration of gonadotrophins. Hum. Reprod. 17(Suppl. 1), 71 (2002).